Portage Biotech Inc.
PRTG
$9.11
$0.252.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.79% | -26.67% | -47.96% | 11.97% | 5.48% |
| Depreciation & Amortization | -23.08% | -33.33% | -53.33% | -27.27% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.60% | -63.37% | -72.90% | -43.15% | -18.01% |
| Operating Income | 54.60% | 63.37% | 72.90% | 43.15% | 18.01% |
| Income Before Tax | 92.46% | 96.16% | 77.57% | 72.62% | 77.23% |
| Income Tax Expenses | -350.00% | 99.97% | -- | 101.38% | 100.01% |
| Earnings from Continuing Operations | 92.47% | 95.24% | 73.63% | 71.92% | 73.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -97.92% | -90.00% | -71.43% | 14.29% | 242.86% |
| Net Income | 92.46% | 95.24% | 73.63% | 72.02% | 73.65% |
| EBIT | 54.60% | 63.37% | 72.90% | 43.15% | 18.01% |
| EBITDA | 54.73% | 63.48% | 72.95% | 43.19% | 18.34% |
| EPS Basic | 93.94% | 96.18% | 78.19% | 76.40% | 78.23% |
| Normalized Basic EPS | -167.08% | 77.14% | 81.10% | 71.88% | 148.35% |
| EPS Diluted | 93.94% | 96.18% | 78.21% | 76.38% | 78.23% |
| Normalized Diluted EPS | -167.08% | 77.14% | 81.10% | 71.88% | 148.35% |
| Average Basic Shares Outstanding | 24.33% | 24.70% | 20.90% | 18.53% | 21.02% |
| Average Diluted Shares Outstanding | 24.33% | 24.70% | 20.90% | 18.53% | 21.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |